News

Filter

Current filters:

VelcadeBiotechnology

European Commission approves added indication for Janssen’s Velcade, in MCL

European Commission approves added indication for Janssen’s Velcade, in MCL

06-02-2015

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag International NV (Janssen)…

BiotechnologyEuropeJanssen-Cilag InternationalJohnson & JohnsonOncologyRegulationVelcade

Multiple myeloma drug market forecast to reach $7.2 billion in 2021

03-10-2012

The multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in…

BiotechnologyCelgeneGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

First-line multiple myeloma patient share in Europe is variable by country

29-08-2012

Despite the considerable heterogeneity across different European countries, surveyed hematologist-oncologists…

AlkeranBiotechnologyCelgeneGlaxoSmithKlineHealthcareJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalThalomidVelcade

Takeda’s Millennium files two sNDAs for Velcade with US FDA

28-04-2011

Japan’s largest drugmaker, Takeda Pharmaceutical (TSE: 4502), together with its US oncology subsidiary…

BiotechnologyMillennium PharmaceuticalsNorth AmericaOncologyPharmaceuticalRegulationTakeda PharmaceuticalsVelcade

Onyx to buy Proteolix for as much as $850 million to get blood cancer drug

12-10-2009

California, USA-based Proteolix has agreed to a takeover bid from Onyx Pharmaceuticals, valuing the firm…

AspirinBayerBayerBiotechnologybortezomibMergers & AcquisitionsNexavarNorth AmericaOncologyPharmaceuticalSorafenibVelcade

Back to top